Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | USP2 | O75604 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31498246 | 0.92 | ALDH1A1 (0.54) | ALDH1A1USP2HPGDCYP3A4ALOX15 | |
| SCHEMBL6480789 | 0.88 | ALDH1A1 (0.49) | ALDH1A1USP2HPGDCYP3A4ALOX15 | |
| SCHEMBL7094868 | 0.80 | ALDH1A1 (0.67) | ALDH1A1USP2HPGDCYP3A4ALOX15 | |
| SCHEMBL11060991 | 0.80 | ALDH1A1 (0.61) | ALDH1A1USP2HPGDCYP3A4ALOX15 | |
| SCHEMBL28367950 | 0.80 | ALDH1A1 (0.49) | ALDH1A1USP2HPGDCYP3A4ALOX15 | |
| SCHEMBL13058109 | 0.79 | ALDH1A1 (0.45) | ALDH1A1USP2HPGDCYP3A4ALOX15 | |
| SCHEMBL7093157 | 0.78 | ALDH1A1 (0.70) | ALDH1A1USP2HPGDCYP3A4ALOX15 | |
| SCHEMBL15874746 | 0.78 | THRA (0.43) | ALDH1A1USP2HPGDCYP3A4ALOX15 | |
| SCHEMBL256700 | 0.77 | — | — | |
| SCHEMBL25237379 | 0.76 | ALDH1A1 (0.46) | ALDH1A1USP2HPGDCYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760752-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-09-19 | — | — | US | disclosed |
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9765065-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765065-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| US-9591935-B2 | Therapeutic substituted cyclopentanes | ALLERGEN, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9591935-B2 | Therapeutic substituted cyclopentanes | ALLERGEN, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20050288240-A1 | Novel-prodrugs for phosphorus-containing compounds | ERION MARK D | 2005-12-29 | — | — | US | disclosed |
| US-6946115-B2 | Prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6294672-B1 | FOR THERAPY OF DIABETES, AND OTHER DISEASES WHERE THE INHIBITION OF GLUCONEOGENESIS, CONTROL OF BLOOD GLUCOSE LEVELS, REDUCTION IN GLYCOGEN STORES, OR REDUCTION IN INSULIN LEVELS IS BENEFICIAL | METABASIS THERAPEUTICS, INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1060182-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | Metabasis Therapeutics, Inc. (US) | 2000-12-20 | — | — | EP | disclosed |
| US-6054587-A | ANTIDIABETIC AGENTS | METABASIS THERAPEUTICS, INC. (US) | 2000-04-25 | — | — | US | disclosed |
| WO-1999045016-A9 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999045016-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS, INC. (US) | 1999-09-10 | — | — | WO | disclosed |
| WO-1998039342-A1 | NOVEL INDOLE AND AZAINDOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288240-A1 | Novel-prodrugs for phosphorus-containing compounds | HCRTR2, CYP2R1, SLC22A8 | ALDH1A1 3799/4885USP2 2749/4885HPGD 3365/4885 |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | ALDH1A1 2097/4885USP2 1865/4885HPGD 878/4885 |
| US-11760752-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors | MCL1, BCLAF1, BCL2A1 | ALDH1A1 353/4885USP2 384/4885HPGD 2935/4885 |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | ALDH1A1 332/4885USP2 3132/4885HPGD 1139/4885 |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | CCRL2, CCR4, ALK | ALDH1A1 2794/4885USP2 3551/4885HPGD 3661/4885 |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | CYP11B2, CYP11B1, HMGCR | ALDH1A1 503/4885USP2 2303/4885HPGD 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.